Navigation Links
Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
Date:10/25/2011

en treated with XEOMIN worldwide since 2005. The U.S. is the 20th country to approve XEOMIN for the treatment of cervical dystonia and blepharospasm.

XEOMIN is the only botulinum toxin product that does not require refrigeration prior to reconstitution. XEOMIN is available in 50-unit and 100-unit vials, which Merz believes may allow for more precise billing and reduce wastage.  

Financial Assistance and Reimbursement Support Services Merz offers two comprehensive programs to provide patients with financial assistance for XEOMIN. The XEOMIN Patient Co-payment Program is easy-to-use and offers eligible patients, who are appropriate for treatment with XEOMIN as determined by their physician, assistance for their actual out-of-pocket costs for treatment with XEOMIN. To be eligible, patients must be at least 18 years of age, currently have commercial health insurance that covers treatment costs for XEOMIN, not be enrolled in or eligible for Medicare, Medicare Advantage, Medicaid, Managed Medicaid, TRICARE (i.e., CHAMPUS), or other state or federally funded insurance plan, and not be a resident in the state of Massachusetts. Eligible treatment-related costs may include the cost of XEOMIN, associated guidance therapy and related administration fees.

The XEOMIN Patient Assistance Program provides XEOMIN at no cost to eligible patients who are experiencing financial hardship, do not have third-party drug coverage, and who are not eligible for government-funded drug programs.

For more information about reimbursement support and financial assistance programs for XEOMIN, visit www.XEOMIN.com, or call 1-888-4-XEOMIN (1-888-493-6646). Dedicated support representatives are available from 8 a.m. until 8 p.m. (EDT), Monday through Friday.

IMPORTANT SAFETY INFORMATIONWARNING: DISTANT SPREAD OF TOXIN EFFECTPostmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
2. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
3. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
6. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- On September 25 to 26, 2014, ... and manufacturing - MEDTEC China  - will mark its ... Convention Center, bringing together close to 300 leading global ... latest medical-grade raw materials, parts and processing technologies. ... free visitor pre-registration to be completed. To date, more ...
(Date:9/16/2014)... , Sept. 16, 2014 Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... to receive formal designation as a "Promising Innovative Medicine" ... (EAMS) launched in the UK in April 2014.  A ... for early access approval under the EAMS.  ...
(Date:9/16/2014)... 2014  Synereca Pharmaceutics, Inc. (SPI), a ... drugs that restore or increase the effectiveness ... million convertible debt financing. Accele Venture Partners, ... Accele Biopharma, Inc., led the financing with ... private not-for-profit corporation focused on growing innovative ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... France, July 10 Ipsogen SA,(Alternext: ALIPS) today reported ... Therapy of Early Breast Cancer indicated for the first,time ... adjunct to the,histological grade. These new guidelines, published online ... European and US experts on,early breast cancer treatment that ...
... , KENILWORTH, N.J., July 9 Schering-Plough Corporation (NYSE: ... the company,s country operation in Japan, has received marketing ... for the treatment of bronchial asthma in adults.(1) , ... of the ASMANEX TWISTHALER in Japan," said Thomas P. ...
Cached Medicine Technology:Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer 2Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer 3ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 2ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 3ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 4
(Date:9/16/2014)... the right balance of nitrogen, phosphorus and potassium is ... State University study finds. , A review of data ... other regions showed that high yields were linked to ... nutrients at specific ratios - nitrogen and phosphorus at ... a ratio of 1-to-1. These nutrient uptake ratios were ...
(Date:9/16/2014)... PA (PRWEB) September 16, 2014 AcousticSheep ... are preparing to launch RunPhones® Wireless, their latest version ... inside a sport-style headband for active people seeking a ... sport headphones on the market and will be ... new RunPhones® Wireless has all of the same great ...
(Date:9/16/2014)... Tara Haelle HealthDay ... -- About 14.5 million U.S. cancer survivors are alive ... American Association for Cancer Research reported Tuesday. These ... include nearly 380,000 survivors of childhood cancer, according to ... in prevention, identification, research and treatment of cancer and ...
(Date:9/16/2014)... September 16, 2014 Novatus, a leading ... new office in London, UK, and appointed Jim Curran ... Europe, the expansion will allow Novatus to target growing ... European customers. , “Novatus is excited ... London is an ideal location to establish our European ...
(Date:9/16/2014)... DC September 16, 2014 The ... coherence tomography (OCT) in primary percutaneous coronary ... annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. ... TCT is the world,s premier educational meeting ... OCT uses light emitted from an intravascular ...
Breaking Medicine News(10 mins):Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3Health News:RunPhones® Prepares to Launch Their New Highly Anticipated Wireless Headphones 2Health News:RunPhones® Prepares to Launch Their New Highly Anticipated Wireless Headphones 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4Health News:Novatus Expands European Operations with a New Office in London 2Health News:Results of OCT STEMI trial reported at TCT 2014 2
... to lead Diabetes Sales, Managed Care and Government ... ... Novo Nordisk, a,healthcare company with an 85-year history of innovation ... Pamela Harris as,vice president for Diabetes Sales, Managed Care and ...
... Two-Week Eye Health Program,in Mandalay, NEW YORK, Feb. ... and the Mandalay Eye and ENT Hospital, ORBIS,International, a ... to Myanmar to conduct its ninth Flying Eye,Hospital program ... February,25 to March 7, 2008., Working together with ...
... drive to digitize data creates need for 99.999% ... ... virtually all healthcare,record keeping and patient care functions converting to ... grade" servers that provide the extreme reliability healthcare,practices need to ...
... rarely detected before it has grown large enough to impair ... disease to fight, especially since chemotherapy is not very effective. ... Faingold may open the door for very promising new treatment ... the cover of the February 2008 issue of Clinical Cancer ...
... Frank E. Staggers, Sr.,M.D. of Oakland, Calif., is a ... Excellence in Volunteerism. Presented by the American Medical,Association (AMA) ... commitment to volunteer medical care to those without access,to ... the award in,association with the Pfizer Medical Humanities Initiative., ...
... Joyce D. Kirkland Essien,M.D., M.B.A., of Atlanta, is ... Presented by the American Medical Association (AMA),Foundation, the award ... the U.S. The AMA Foundation presents the award in,association ... will be presented on Monday, March 31st, at the ...
Cached Medicine News:Health News:Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President 2Health News:ORBIS International's Flying Eye Hospital Returns to Myanmar 2Health News:Stratus Medical Grade Servers Deliver 24/7 Online Information Access and Application Availability 2Health News:Stratus Medical Grade Servers Deliver 24/7 Online Information Access and Application Availability 3Health News:HSP90: New point of view on melanoma of the eye, at the MUHC 2Health News:AMA Foundation Honors Oakland, California Physician for Volunteerism 2Health News:AMA Foundation Honors Atlanta Physician for Increasing Access to Health Care in the U.S. 2
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Concave inner surface to conform to the globe. Indications: Wide scleral bed. Outside diameter 32 mm....
Medicine Products: